# Ayana capital

> Ayana capital is a VC fund in Dallas backing Medical, Biopharma and Health Care. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Dallas, United States
- Total investments: 2
- Last investment: Aug 2024
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ayana-capital-llc/
- Website: https://www.ayana.capital

Ayana capital is a VC fund in Dallas focused on Medical and Biopharma. Ayana Capital invests in Pre-seed through Series A rounds and aim to create strong ties and meaningful synergies.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Biopharma | 1 | 50% |
| Health Care | 1 | 50% |
| Biotechnology | 1 | 50% |
| Artificial Intelligence | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Healx | Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AItechnology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact. Founded in Cambridge, UK, in 2014 by Dr Tim Guilliams (a Biochemical Engineer and tech entrepreneur) and Dr David Brown (co-inventor of Viagra and former Global Head of Drug Discovery at Roche), Healx has raised $70 million to date. For more information, visit www.healx.io. | $47M | Series C | Aug 01, 2024 |  |
| Astek Diagnostics | Astek Diagnostics is building a platform (Eugris) that guides physicians in prescribing appropriate antibiotics for patients with bacterial sepsis in one hour. It is done by detecting the oxygen consumption of the bacteria | $2M | Seed | Jun 05, 2023 |  |

2 of 2 investments shown.

## Co-investors
- [O2h Ventures](https://shizune.co/investors/profile/2h-ventures) — VC Fund, 1 deal together
- [Atomico](https://shizune.co/investors/profile/atomico) — VC Fund, 1 deal together
- [Balderton Capital](https://shizune.co/investors/profile/balderton-capital) — VC Fund, 1 deal together
- [b2venture](https://shizune.co/investors/profile/btovpartners) — VC Fund, 1 deal together
- [Global Brain Corporation](https://shizune.co/investors/profile/global-brain-corporation) — VC Fund, 1 deal together
- [TEDCO](https://shizune.co/investors/profile/maryland-technology-development-corporation) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Ayana capital invest in?

Ayana capital invests primarily in Medical, Biopharma and Health Care startups, most often at Series C stage. Most of the 2 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ayana capital last invest?

The most recent investment recorded for Ayana capital closed in Aug 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co